UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 16, 2011
ADVANCED MEDICAL ISOTOPE CORPORATION
(Name of registrant as specified in its charter)
|
Delaware
|
0-53497
|
80-0138937
|
|
(State or other jurisdiction of
Incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification Number)
|
|
6208 W Okanogan Ave.
Kennewick WA 99336
|
99336
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (509) 736-4000
|
N/A
|
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 8.01 Other Events.
Contrary to certain statements made under "Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Competitors" in our Form 10-Q filed with the SEC on August 4, 2011 in relation to Nordion Inc. (“Nordion”), we understand that Atomic Energy of Canada Limited’s National Research Universal reactor returned to operation in August, 2010 after a temporary shut down, and that accordingly, Nordion resumed its role in the medical isotope supply chain and continues to be a supplier to the U.S.
market.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ADVANCED MEDICAL ISOTOPE CORPORATION
|
|||
|
Date: September 16, 2011
|
By:
|
/s/ James C. Katzaroff
|
|
|
Name:
|
James C. Katzaroff
|
||
|
Title:
|
Chairman and Chief Executive
Officer
|
||
2